On the other hand, in cases of low-tumor burden or in fragile patients due to age, comorbidities or an ECOG PS 2, it may be more prudent to use single anti-PD-1 agents, given their better safety profile compared to the anti-PD1/anti-CTLA4 combination. Here, PDCD1 is linked to neoplasm.